Diabetic Kidney Disease (DKD) Comprehensive Management — free guideline decision tool
This tool frames multi-pillar management of diabetic kidney disease by eGFR and albuminuria, spanning RAAS inhibition, SGLT2 inhibitors, finerenone, glucose-lowering, and blood pressure, per KDIGO 2022.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| eGFR | 45 mL/min/1.73m² |
|---|---|
| Albuminuria (UACR ≥ 30 mg/g) | Present |
→DKD comprehensive managementeGFR 45, with albuminuria
- RAAS inhibitor：ACEi or ARB to the maximum tolerated dose (first-line with comorbid hypertension and albuminuria); monitor creatinine and potassium after starting/adjusting
- SGLT2 inhibitor：For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected
- Finerenone：T2DM + eGFR ≥ 25 + UACR ≥ 30 + normal potassium, on a maximum tolerated ACEi/ARB (± SGLT2i) with residual albuminuria/risk: add the nonsteroidal MRA finerenone for cardiorenal benefit; monitor potassium
| eGFR | 45 mL/min/1.73m² |
|---|---|
| Albuminuria (UACR ≥ 30 mg/g) | Absent |
→DKD comprehensive managementeGFR 45, no albuminuria
- RAAS inhibitor：With comorbid hypertension, ACEi/ARB may be used; without albuminuria or hypertension, do not force use for renal protection
- SGLT2 inhibitor：For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected
- Glucose-lowering：Metformin first-line at eGFR ≥ 30; if metformin + SGLT2i still misses target or cardiovascular benefit/weight loss is needed, second-line GLP-1 RA; individualize HbA1c
Common questions
What is Diabetic Kidney Disease (DKD) Comprehensive Management?
This tool frames multi-pillar management of diabetic kidney disease by eGFR and albuminuria, spanning RAAS inhibition, SGLT2 inhibitors, finerenone, glucose-lowering, and blood pressure, per KDIGO 2022.
How is Diabetic Kidney Disease (DKD) Comprehensive Management calculated? What is the core formula?
Pillars by eGFR/albuminuria: ACEi/ARB (albuminuria), SGLT2i (eGFR ≥ 20), finerenone (eGFR ≥ 25 + UACR ≥ 30 + normal K on RASi ± SGLT2i), metformin (eGFR ≥ 30) → GLP-1 RA, statin + BP < 130/80 for all.
When is Diabetic Kidney Disease (DKD) Comprehensive Management used?
Use to assemble the DKD regimen: RAAS blockade for albuminuria/hypertension, an SGLT2i at eGFR ≥ 20, finerenone for residual albuminuria, and statin/BP/lifestyle for all patients.
What are the key clinical points for Diabetic Kidney Disease (DKD) Comprehensive Management?
An SGLT2i is added for cardiorenal protection independent of glycemia, and a transient eGFR dip after starting is expected, not a reason to stop. (original synthesis · not guideline verbatim) Finerenone is added for residual albuminuria/risk on maximal RASi ± SGLT2i when potassium is normal, with potassium monitoring. Every DKD patient receives a statin, BP target < 130/80, and lifestyle measures, with periodic eGFR/UACR/potassium monitoring.
What are the limits and cautions when using Diabetic Kidney Disease (DKD) Comprehensive Management?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Diabetic Kidney Disease (DKD) Comprehensive Management calculated in practice? Can you show a worked example?
Inputs: eGFR 45 mL/min/1.73m², Albuminuria (UACR ≥ 30 mg/g) Present → Result: DKD comprehensive management eGFR 45, with albuminuria（RAAS inhibitor: ACEi or ARB to the maximum tolerated dose (first-line with comorbid hypertension and albuminuria); monitor creatinine and potassium after starting/adjusting, SGLT2 inhibitor: For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected, Finerenone: T2DM + eGFR ≥ 25 + UACR ≥ 30 + normal potassium, on a maximum tolerated ACEi/ARB (± SGLT2i) with residual albuminuria/risk: add the nonsteroidal MRA finerenone for cardiorenal benefit; monitor potassium） Inputs: eGFR 45 mL/min/1.73m², Albuminuria (UACR ≥ 30 mg/g) Absent → Result: DKD comprehensive management eGFR 45, no albuminuria（RAAS inhibitor: With comorbid hypertension, ACEi/ARB may be used; without albuminuria or hypertension, do not force use for renal protection, SGLT2 inhibitor: For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected, Glucose-lowering: Metformin first-line at eGFR ≥ 30; if metformin + SGLT2i still misses target or cardiovascular benefit/weight loss is needed, second-line GLP-1 RA; individualize HbA1c）
Run Diabetic Kidney Disease (DKD) Comprehensive Management now
This tool frames multi-pillar management of diabetic kidney disease by eGFR and albuminuria, spanning RAAS inhibition, SGLT2 inhibitors, finerenone, glucose-lowering, and blood pressure, per KDIGO 2022.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.